To quote Jennifer Lopez ,“C’mon people, let’s get loud!” Hang up your lab coat, leave your pad folios and ipads behind, and dust off your protest sign, it’s time to make some noise for medical research!
you are not alone! Comparative effectiveness research (CER) is a tool that can have a significant effect on those receiving health care, particularly older Americans. When used correctly, CER can help ensure that seniors facing illnesses receive the best care for their condition. However, many open questions remain around this critical issue.
This week the Alliance for Aging Research and the U.S. Administration on Aging (AoA) released a new white paper titled Translating Innovation to Impact: Evidence-based interventions to support people with Alzheimer's disease and their caregivers at home and in their communities. The white paper was written by Katie Maslow, MSW, Scholar-in-Residence at the Institute of Medicine, but the findings in the paper are the result of a review of the state of the art of non-pharmacological treatments and care practices that began with a public-private meeting on June 28, 2012.
The Alliance for Aging Research was pleased to be a co-sponsor of the National Pharmaceutical Council’s Myth of the Average Patient Conference in Washington, D.C. I had the opportunity to attend the event and share my thoughts on why the topic of heterogeneity among patients is important to consider when conducting comparative effectiveness research.
David Stipp is a prominent science writer who has focused on medicine, science, and aging for decades for publications like The Wall Street Journal, Fortune, Slate, Science, and more. The Alliance for Aging Research was very fortunate to have Stipp author a whitepaper--The Transformative Promise of Aging Science--to help launch our Healthspan Campaign earlier this year.
TEDMED left its home in San Diego this year to debut at the Kennedy Center in DC, and it certainly didn’t disappoint. The speaker line-up was full of big names like Francis Collins, Katie Couric, and Billie Jean King and the big ideas ranged from designing new DNA, to using mathematics to personalize cancer treatments, to the shift of the scientific method in the face of a data-dominated world. One particularly interesting talk came from our own President & CEO Daniel Perry, who spoke about whether or not “Cells Have a Mid-Life Crisis.”